American Society Of Hematology
GLP-1s reduce thrombosis risk among people with diabetes, regardless of obesity
SAN DIEGO — Glucagon-like peptide-1 receptor agonists reduced risk for venous thromboembolism among patients with type 2 diabetes, according to retrospective study results presented at ASH Annual Meeting and Exposition.
Socioeconomic factors a barrier to HSCT for people with acute myeloid leukemia
SAN DIEGO — Socioeconomic disparities affect access to allogeneic hematopoietic stem cell transplantation for people with acute myeloid leukemia, according to findings presented at ASH Annual Meeting and Exposition.
Epcoritamab exhibits ‘very encouraging’ efficacy in heavily pretreated CLL
SAN DIEGO — Epcoritamab exhibited encouraging efficacy among heavily pretreated patients with advanced chronic lymphocytic leukemia, according to study results presented at ASH Annual Meeting and Exposition.
ASH honors two individuals for sickle cell disease advocacy efforts
American Society of Hematology presented Advocacy Awards to two individuals at this year’s ASH Annual Meeting.
Daratumumab superior to active monitoring for high-risk smoldering multiple myeloma
SAN DIEGO — Daratumumab monotherapy significantly delayed progression of high-risk smoldering multiple myeloma to active multiple myeloma compared with active monitoring, according to results of the randomized phase 3 AQUILA study.
Mitigating financial toxicity ’better than any drug’ for people with cancer
SAN DIEGO — Successfully addressing financial toxicity for people with blood cancer will require substantial efforts from a variety of stakeholders, according to a speaker at ASH Annual Meeting and Exposition.
Hydroxyurea provides ‘remarkable clinical benefit’ in hemoglobin SC disease
SAN DIEGO — Hydroxyurea conferred benefit to children and adults with hemoglobin SC disease, according to study results presented at ASH Annual Meeting and Exposition.
Bicistronic CAR-T effective for children with relapsed B-ALL
SAN DIEGO — A bicistronic chimeric antigen receptor T-cell therapy induced durable response for most children with relapsed or refractory B-lineage acute lymphoblastic leukemia, findings presented at ASH Annual Meeting and Exposition showed.
Addition of blinatumomab to chemotherapy improves outcomes for children with B-cell ALL
SAN DIEGO — The addition of blinatumomab to chemotherapy extended DFS for children with newly diagnosed B-cell acute lymphoblastic leukemia, according to results of a randomized phase 3 trial presented at ASH Annual Meeting and Exposition.
Smoking associated with mutations linked to myelodysplastic syndrome
SAN DIEGO — Genetic mutations related to myelodysplastic syndrome occurred significantly more often among people who smoked than nonsmokers, according to study results presented at ASH Annual Meeting and Exposition.